A phase I study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma
Thomas J. Galloway, Lori J. Wirth, Alexander D. Colevas, Jill Gilbert, Julie E. Bauman, Nabil F. Saba, David Raben, Ranee Mehra, Anna W. Ma, Ruzanna Atoyan, Jing Wang, Barbara Burtness, Antonio Jimeno
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'A phase I study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma'. Together they form a unique fingerprint.